Ayşe Güler EROĞLU, Reyhan DEDEOĞLU, Fatih VAROL, Levent SALTIK, Sezen ATİK UGAN, Halit ÇAM

Bonzai kullanımına bağlı kalp ve damar sistemi yan etkileri: İki olgu sunumu

Sentetik kanabinoidlerin (bonzai) kalp ve damar sistemine etkileri ko-nusunda bilinenler sınırlıdır. Bu yazıda bonzai kullanımı sonrası farklıkardiyolojik yan etkiler izlenen iki olgu sunulmuştur.İlk olgumuz olan 16 yaşında erkek hasta bir saat önce başlayan şiddetligöğüs ağrısı ile acil servisimize başvurdu. Elektrokardiyografk incele-mesinde miyokard enfarktüsü şüphesine neden olan DII, DIII, AVF, V5-V6 derivasyonlarında 3 mmden fazla ST segment elevasyonları izlendi.Kardiyak kateterizasyon uygulanan hastanın koroner anjiyografsi nor-mal olarak saptandı. Hasta yeniden sorgulandığında bonzai kullandığıöğrenildi. On sekiz yaşında bonzai bağımlısı olan ikinci olgu bilinçbulanıklığı nedeniyle arkadaşları tarafından acil servise getirildi. Kalptepe atımı 40/dk ya gerileyen ve birlikte hipertansiyonu izlenen hasta-ya, bradikardisinin derinleşmesi nedeni ile dopamin tedavisi başlandı.Ancak kan basıncının hızla yükselmesi üzerine dopamin tedavisi kesi-lerek kalp atım hızı ve kan basıncı izlemi yapıldı.Acil servise göğüs ağrısı ve kalp damar sistemi ile ilgili yakınmalarlabaşvuran hastalarda bonzai kullanımı akılda tutulmalıdır.

Cardiovascular side effects related with use of Bonzai : Two case reports

Information about the effects of synthetic cannabinoids (bonzai) on thecardiovascular system is limited. In this article, two patients in whomdifferent cardiological side effects were observed following use of bon-zai were presentedOur frst patient who was a 16-year old boy presented to our emergencydepartment with severe chest pain which had started one hour before.On electrocardiographic examination, ST segment elevations greaterthan 3 mm were observed in DII, DIII, AVF and V5-V6 derivations whichcaused to suspicious myocardial infarction. Cardiac catheterization wasperformed and coronary angiographic fndings were found to be nor-mal. When the patient was questioned again, it was learned that he used bonzai . The second patient who was aged 18 years and addicted to bon-zai was brought to our emergency department by his friends because ofclouding of consciousness. Dopamin treatment was started in the patientwhose cardiac apical beat reduced to 40/min and who was found to de-velop hypertension, because bradycardia worsened. However, the bloodpressure increased rapidly and dopamin treatment was stopped. Heartrate and blood pressure monitoring was continued.Use of bonzai should be kept in mind in patients who present to emer-gency departments with chest pain and complaints related with the car-diovascular system.

PDF

___

1. Sedefov R, Gallegos A, King L, et al. Understanding the spice phenomenon. Thematic papers, European Moni- toring Centre for Drugs and Drug Addiction; 2009.
2. OMalley PM, Bachman JG, Schulenberg JE, Arbor A. MI Institute for Social Research, The University of Michigan; 2012. Monitoring the future national results on adoles- cent drug use: overview of key fndings, 2011.
3. (UNODC), U.N.O.o.D.a.C. Synthetic cannabinoids in her- bal products , 2011. http://www.unodc.org/documents/ scientifc/Synthetic_Cannabinoids.pdf.
4. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S , Huestis MA. Synthetic cannabinoids: epidemio- logy, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014; 144: 12-41. [CrossRef]
5. Gurdal F, Asirdizer M, Aker RG, et al. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. J Forensic Leg Med 2013; 20: 667-72. [CrossRef]
6. Zubrzyckı M, Liebold A, Janecka A, Zubrzycka M. A new face of endocannabınoids in pharmacotherapy. Part 1: protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol 2014; 65: 171-81.
7. Bachs L, Mørland H. Acute cardiovascular fatalities fol- lowing cannabis use. Forensic Sci Int 2001; 124: 200-3. [CrossRef]
8. Mir A, Obafemi A, Young A, Kane C. Myocardial infarcti- on associated with use of the synthetic cannabinoid K2. Pediatrics 2011; 128: 1622-7. [CrossRef]
9. Mckeever RG, Vearrier D, Jacobs D, Lasala G, Okaneku J, Greenberg MI. K2-not the spice of life; synthetic canna- binoids and ST elevation myocardial infarction: J Med Toxicol 2014.[Epub ahead of print] [CrossRef]
10. Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol, 2014. [Epub ahead of print] [CrossRef]
11. Krylatov AV, Maslov LN, Ermakov SI, et al. Signifcance of cardiac cannabinoid receptors in regulation of cardiac rhythm, myocardial contractility, and electrophysiologic processes in heart. Izv Akad Nauk Ser Biol 2007; 1: 35-44. [CrossRef]
12. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confrmed consumption of synthetic cannabinoids: clinical and laboratory fndings. Addiction, 2013; 108: 534-44. [CrossRef]